Microwave Mediated Synthesis and Analytical Method Development for the Estimation of Novel 1,4-Dihydropyridines in Bulk by RP-HPLC

Authors Anupreet Kaur¹, Jaspreet Kaur¹, Ranju Bansal²

Affiliations

- 1 University Institute of Engineering & Technology, Panjab University, Chandigarh, India
- 2 University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India

Key words

Calcium channel blockers, 1,4-dihydropyridines, microwave synthesis, vasodilation, RP-HPLC

Bibliography

DOI https://doi.org/10.1055/s-0043-120663 Published online: 2017 | Drug Res © Georg Thieme Verlag KG Stuttgart · New York ISSN 2194-9379

Correspondence

Ranju Bansal University Institute of Pharmaceutical Sciences Panjab University Sector 14 Chandigarh-160014 Tel.: +91/172/2541 142, Fax: +91/172/2543 101 ranju29in@yahoo.co.in



ABSTRACT

The present work describes a rapid and green microwave mediated method for the synthesis and a simple and precise isocratic reverse phase HPLC method for the estimation of the biologically significant dihydropyridines. The conventional synthesis of these dihydropyridines has been previously reported from our lab. The analysis of a standard solution (1 mg/ ml) was accomplished on a symmetry (4.6 mm I.D x 250 mm) C-18 column using mobile phase acetonitrile:water:triethylam ine (TEA) (70:30:0.1 v/v/v) at a flow rate of 0.7 ml/min. Detection was monitored at 354 nm. The retention time for all the compounds was accomplished as less than 10 min. The compounds showed the linear response over the concentration range 10–100 µg/ml. The study is aimed to develop a rapid method for the quantification of these potent molecules. Various parameters like linearity (10-100 µg/ml), USP tailing and plate count were found to be satisfactory. The investigated parameters were studied with the freshly prepared solutions.

Introduction

Antihypertensive drugs are prescribed worldwide to cure the common cardiovascular diseases and related complications [1]. Calcium channel blockers (CCBs) have emerged as the most favourable choice for treating hypertension as they have been proven to control the various coronary and stroke related risks [2, 3]. CCBs of the type 4-aryl-1,4-dihydropyridine are of interest to medicinal chemists for the treatment of cardiovascular disorders because of their high potency, selectivity of action and heterogeneity [4, 5]. CCBs control the calcium influx through voltage-dependant calcium channels in the smooth muscles and dilate coronary and peripheral arteries and reduce heart after-load [6–8]. Dihydropyridines (DHPs) have been reported to be the most frequently prescribed CCBs for the treatment of hypertension in many regions of eastern Asian countries including China [9, 10]. The fascinating biological spectra of the calcium channel antagonists have led to the development of newer technologies to improve conventional methods of preparation using various catalysts such as copper (II) triflate [11], molecular iodine [12], organocatalyst [13], trifluoroacetic acid [14]. Further to overcome inherited drawbacks of longer reaction times and poor yields, microwave assisted organic synthesis (MAOS) [15, 16] has been adopted. Syntheses of DHP and pyridines have been demonstrated using microwave in batch [17] and flow reactor in the presence of a catalyst to replace the traditional two-step synthesis [18].

Synthesis of some new analogues of 4-aryl-1,4-dihydropyridines (1,4-DHPs) possessing significant calcium channel blocking activity along with good vasodilatory profile has been reported [14] from our lab. With chemical synthesis, achieving high yields in reasonable times is a great challenge, therefore there is a need to develop an efficient method to synthesize these compounds with minimum hazards and less time. We have tried to develop an efficient and greener method for the preparation of novel 1,4-DHPs exhibiting excellent vasodilation activity as an environment friendly approach. As the regulatory authorities have made the complete as-



▶ Fig. 1 Synthetic route to the synthesis of the dihydropyridines. Reagents and reaction conditions: a Microwave 75 °C, 25-30 min, Liq. NH₃ b Microwave 75 °C, 50 min, EMK, anhyd. K₂CO₃, respective amine.

sessment even more rigorous for new drug candidates and understanding that the detection limits are completely varied for a vast range of applications, consistent increase in the method development for commercial calcium channel blockers such as amlodipine [19–21] felodipine [22] and nimodipine is obvious [23].

Analytical methods based on HPLC [24, 25] have long been the methods of choice for the quantification of dihydropyridines as the technique is sensitive and rapid. High therapeutic index of dihydropyridines has promoted the analytical method development for their assessment in bulk, dosage and in biological fluids. Literature study reveals that several analytical methods for the quantitative determination of dihydropyridines such as spectrophotometry [26, 27], spectrofluorimetry [28], electrochemical methods [29] and HPLC-MS [30, 31] have been reported. The inherent simplicity, reproducibility and highly selective nature of analysis make the liguid chromatography based estimations as the most suitable for guality control laboratories. The first phase of the research work is aimed to develop a greener and rapid synthetic method for 1,4-DHP via microwave irradiation and the second phase involves development of a simple and efficient RP-HPLC method for the quantitative estimation of these potent dihydropyridines.

Materials and Methods

General Information

All reactions were carried out under an inert atmosphere, unless otherwise stated using microwave synthesizer (Initiator Exp. Bio-

tage). Solvents were dried and purified by standard methods prior to use. The progress of all reactions was monitored by TLC using glass plates pre-coated with silica gel 60 F254 with a thickness of 0.5 mm. The Veego melting point apparatus (VMP-D) was used to measure melting points of the synthesized compounds. The melting points reported are uncorrected.

Microwave mediated synthesis

Synthesis of the parent 1,4-dihydropyridine scaffold 1 was carried out by reacting 4-hydroxybenzaldehyde, methyl acetoacetate and liquor ammonia under stirring at 75°C in a microwave vial for 25 min (▶ Fig. 1). The residue obtained was washed with cold ethanol (25%) and crystallised in acetone. Further alkylation of the parent dihydropyridine with hydrochlorides of 1-(2-chloroethyl)pyrrolidine and 2-(diethylamino)ethyl chloride in ethyl methyl ketone (EMK) using anhydrous potassium carbonate afforded compounds 2 and 3, respectively. Reaction progress was monitored with the help of the TLC. The comparative data for the formation of dihydropyridines using conventional and microwave methods has been provided in ▶ Table 1.

Analytical method development

Chromatographic conditions

The chromatographic conditions for analysis of the molecules throughout the experimental work were maintained as detailed in **Table 2**. All analyses were performed in an air-conditioned lab.



Comp.	R	т.р. (°С)	Crystallizing Solvent	Time/Yield	
				Conventional Method	Microwave Method
1	ОН	231-233	Acetone	3h/87.43%	25 min /51.1 %
2	-OCH ₂ CH ₂ N	155-156	Ether/ethyl acetate	8h/41.48%	50 min /40.21 %
3	–OCH ₂ CH ₂ N(CH ₃) ₂	169-171	Ether/ethyl acetate	8 h/45.78 %	50 min /41.32 %

Standard Solution

An accurately weighed pure sample (10 mg) was dissolved in methanol (10 ml) to make a stock solution. The solution was sonicated for 5 min. Dilutions $(10-100 \,\mu\text{g/ml})$ were further made using this stock solution. The solutions were filtered through 0.22 μ m PTFE membrane filter (Millipore) and were used for analysis.

Results and Discussion

Microwave mediated synthesis

As observed from **Table 1**, the current synthetic method has a clear advantage of shorter reaction time and higher yields in the absence of any catalyst and solvent for the synthesis of dihydropyridine analogues.

HPLC method development

To achieve the best chromatographic conditions, the detection wavelength (200–400 nm) and the mobile phase composition were adequately selected. Pre-conditioning of the RP-phase columns before runs was always performed by gradually changing the flow rates and mobile phase composition in the gradient mode. The main objective was to develop a reverse phase liquid chromatographic method allowing the determination of dihydropyridine analogues in the shortest time. At 354 nm the dihydropyridines showed enough absorption and the calibration has a good linearity and the best S/N ratio. Because of less polar nature of dihydropyridines they are readily soluble in organic solvents such as ethanol, methanol and DMSO and hence strongly retained on RP-HPLC columns. The column selection has been done based on certain parameters including back-pressure, peak shape, theoretical plates and reproducibility of retention times on these columns.

Different types of C-18 columns ($4.6 \times 250 \text{ mm}$) (BEH, SUN, Symmetry and Spherisorb from Waters) with various mobile phase combinations were investigated. This included methanol + water; acetonitrile + water; methanol + water + TEA and acetonitrile + water + TEA systems in gradient mode. Though all the columns performed satisfactorily for one or the other compound

Table 2 Details of the various parameters used for RP-HPLC method.

System: Waters HPLC Model 2996 Column: Symmetry (4.6 mm l.D x 250 mm) C-18 Detector: Variable wavelength programmable UV/VIS detector PDA Mobile phase: Acetonitrile + Water + Triethylamine (TEA) (70:30:0.1) Detection wavelength: 354 nm Mode: Isocratic Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	
Column: Symmetry (4.6 mm I.D x 250 mm) C-18 Detector: Variable wavelength programmable UV/VIS detector PDA Mobile phase: Acetonitrile + Water + Triethylamine (TEA) (70:30:0.1) Detection wavelength: 354 nm Mode: Isocratic Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	System: Waters HPLC Model 2996
Detector: Variable wavelength programmable UV/VIS detector PDA Mobile phase: Acetonitrile + Water + Triethylamine (TEA) (70:30:0.1) Detection wavelength: 354 nm Mode: Isocratic Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	Column: Symmetry (4.6 mm I.D x 250 mm) C-18
Mobile phase: Acetonitrile + Water + Triethylamine (TEA) (70:30:0.1) Detection wavelength: 354 nm Mode: Isocratic Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	Detector: Variable wavelength programmable UV/VIS detector PDA
Detection wavelength: 354 nm Mode: Isocratic Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	Mobile phase: Acetonitrile + Water + Triethylamine (TEA) (70:30:0.1)
Mode: Isocratic Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	Detection wavelength: 354 nm
Syringe: Hamilton syringe. (7202, 25 µL) Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual Temperature: Room temperature	Mode: Isocratic
Flow rate: 0.7 ml/min. Injector: Rheodyne-7725i Type of Injector: Manual	Syringe: Hamilton syringe. (7202, 25 µL)
Injector: Rheodyne-7725i Type of Injector: Manual	Flow rate: 0.7 ml/min.
Type of Injector: Manual	Injector: Rheodyne-7725i
Temperature: Room temperature	Type of Injector: Manual
	Temperature: Room temperature



► Fig. 2 Optimised chromatogram of compound 1 (100 µg/ml).

but the aim was to develop one column for all the compounds under investigation. The best choice came as symmetry column, which could resolve all the compounds in less than 10 min of run time (▶ Figs. 2–4). Selected stationary phase has shown better repeatability with low back pressure. Acetonitrile was preferred as it has shown lesser UV cut-off response compared to methanol. This was further improved for the individual compounds and the run time was brought down to less than 6 min. Addition of TEA led to improved baseline and peak quality.

Validation of system suitability parameters

According to USP, system suitability tests were carried out on standard stock solution of compounds. $20\,\mu$ L of the solution was



▶ Fig. 3 Optimised chromatogram of compound 2 (100 µg/ml).



▶ Fig. 4 Optimised chromatogram of compound 3 (100 µg/ml).

▶ Table 3 Various chromatographic parameters obtained with symmetry column.

injected into the chromatographic conditions. Parameters studied to evaluate the suitability of system were retention time, area under curve, USP tailing and number of theoretical plates, statistical parameters and LOD/LOQ values (**> Table 3**).

The straight line graph (with zero intercept value) has been obtained after plotting the peak area values as a function of the concentration values (in triplicates). This clearly confirms the linearity through this measured range as well as lack of bias. The statistical parameters of the calibration have been described in **► Table 3**.

The mobile phase acetonitrile: water: TEA (70:30:0.1) (v/v/v %) was selected as it gave sharp peaks of the compounds with retention time of less than 6 min. Wavelength was selected by scanning standard solutions of drugs over 200 nm to 400 nm. The compounds showed good response at 354 nm. The low value of standard deviation indicates that system suitability parameters are stable over the given chromatographic conditions. The value of coefficient of correlation reflects the method is linear over the concentration range of 10-100 μ g/ml. The low relative standard deviation values indicate a high accuracy of the method.

Conclusion

A rapid, green and efficient microwave irradiated synthesis methodology has been developed for the preparation of novel biologically active dihydropyridines in this study. Furthermore, for the estimations of these dihydropyridines a simple, sensitive and precise RP-HPLC method has been developed. Since the analysis is completed within 6 min, it clearly indicates that the method is rapid and thus it could be used for routine studies of the potent dihydropyridine based drug candidates.

Acknowledgement

Authors are thankful to UGC, India and TEQIP – II for financial assistance.

Ethical approval: This article does not contain any studies with human participants performed by any of the authors.

Conflict of Interest

Authors declare no conflict of interest.

Parameters	(1)	(2)	(3)
Retention Time	3.28 min	5.6 min	4.6 min
Peak Area (mean)	1192170	1109994	1134391
Theoretical Plates(mean)	2083	13277	6647
Tailing Factor(mean)	0.94	1.02	0.77
LOD;LOQ	0.628µg/ml; 2.09µg/ml	0.45µg/ml; 1.53µg/ml	0.58µg/ml; 1.19µg/ml
Statistical parameters of the calibration	1 st order linear curve; r ² =0.9989	1 st order linear curve; r ² =0.9984	1 st order linear curve; r ² =0.9970

- Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol 2017; 14: 67–72
- [2] Jarari N, Rao N, Peela JR et al. A review on prescribing patterns of antihypertensive drugs. Clin Hypertens 2015; 22: 7 Im Internet http:// www.clinicalhypertension.com/content/22/1/7
- [3] Ioan P, Carosati E, Micucci M et al. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 1): Action in ion channels and GPCRs. Curr Med Chem 2011; 18: 4901–4922
- [4] Mancia G, Fagard R, Narkiewicz K et al. 2013; Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC).
 J Hypertens 2013; 31: 1925–1938 Im Internet http://content.
 wkhealth.com/linkback/openurl?sid = WKPTLP:landingpage&an = 00004872-201310000-00002
- [5] Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-Converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386–392 Im Internet http://hyper.ahajournals.org/cgi/doi/10.1161/01. HYP.0000174591.42889.a2
- [6] Shaldam MA, Elhamamsy MH, Esmat EA et al. 1,4-Dihydropyridine calcium channel blockers: Homology modeling of the receptor and assessment of structure activity relationship. ISRN Med Chem 2014; 2014: 1–14Im Internet http://www.hindawi.com/journals/ isrn/2014/203518/
- [7] Khedkar S, Auti P. 1, 4-Dihydropyridines : A class of pharmacologically important molecules. Mini Rev Org Chem 2014; 14: 282–290
- [8] Haller H. Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract 2008; 62: 781–790
- [9] Wang J-G, Kario K, Lau T et al. Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: A scientific statement from the Asian Pacific Heart Association. Hypertens Res 2011; 34: 423–430 Im Internet http://www.nature. com/doifinder/10.1038/hr.2010.259
- [10] Mori H, Ukai H, Yamamoto H et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143–151
- [11] Pattan SR, Rasal VP, Venkatramana NV et al. Synthesis and evaluation of some 1, 4- dihydropyridine and their derivatives as antihypertensive agents. Indian J Chem Sect B 2007; 46: 698–701
- [12] Akbari JD, Tala SD, Dhaduk MF et al. Molecular iodine catalyzed one-pot synthesis of some new Hantzsch 1,4- dihydropyridines at ambient temperature. Arkivoc 2008; 12: 126–135
- [13] Kumar A, Maurya RA. Organocatalysed three-component domino synthesis of 1,4-dihydropyridines under solvent free conditions. Tetrahedron 2008; 64: 3477–3482
- [14] Jain P, Narang G, Jindal DP et al. Synthesis of a new series of 4-aryl-1,4dihydropyridines with calcium channel blocking and vasodilatory activity. Pharmazie 2006; 61: 400–405
- [15] Singh L, Ishar MPS, Elango M et al. Synthesis of unsymmetrical substituted 1, 4-Dihydropyridines through thermal and microwave assisted [4+2] cycloadditions of 1-Azadienes and allenic esters. 2008; 1: 2224–2233
- [16] Bandyopadhyay D, Maldonado S, Banik BK. A microwave-assisted Bismuth nitrate-catalyzed unique route toward 1,4-dihydropyridines. Molecules 2012; 17: 2643–2662

- [17] Bagley MC. One-step synthesis of pyridines and dihydropyridines in a continuous flow microwave reactor. Sp2 2014; 24–26
- [18] Christiaens S, Vantyghem X, Radoiu M et al. Batch and continuous flow preparation of hantzsch 1,4-dihydropyridines under microwave heating and simultaneous real- Time monitoring by raman spectroscopy. An exploratory study. Molecules 2014; 19: 9986–9998
- [19] Pawar HA, Yadav A. Development and application of RP-HPLC method for dissolution study of oral formulations containing amlodipine besylate. Indian J Chem Technol 2016; 23: 210–215
- [20] Hassan SA, Elzanfaly ES, El-Zeany SBA et al. Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and atorvastatin in the presence of their acidic degradation products in tablets. Acta Pharm 2016; 66: 479–490
- [21] Patel J, Patel M. RP-HPLC method development and validation for the simultaneous estimation of ramipril and amlodipine besylate in capsule dosage form. J Chem Pharm Res 2014; 6: 725–733 Im Internet https://www.scopus.com/inward/record.uri?eid = 2-s2.0-84924709904&partnerID = 40&md5 = 85d0f6bb892601b4cc95dabcbc08c711
- [22] Setti A, Takhelmayum PD, Sarikonda S et al. Molecular interaction studies of felodipine and voltage gated L-type calcium channel. 2014; 24: 15–20
- [23] Shang X, Ma S, Li Z. Development and Validation of a RP-HPLC Method for Determination of Nimodipine in Sustained Release Tablets. 2013; 2013:
- [24] Baranda AB, Jiménez RM.AR Simultaneous determination of five 1,4-dihydropyridines in pharmaceutical formulations by high-performance liquid chromatography-amperometric detection. J Chromatogr A 2004; 1031: 275–280
- [25] Baranda AB, Etxebarria N, Jimenez RM et al. Improvement of the chromatographic separation of several 1,4-dihydropyridines calcium channel antagonist drugs by experimental design. J Chromatogr Sci 2005; 43: 505–512 Im Internet http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd = Retrieve&db = PubMed&dopt = Citation&list_ uids = 16438789 %5Cn http://chromsci.oxfordjournals.org/ content/43/10/505.full.pdf
- [26] Rahman N, Najmul S, Azmi H. New spectrophotometric methods for the determination of nifedipine in pharmaceutical formulations. Acta Biochim Pol 2005; 52: 915–922
- [27] Wankhede SB, Raka KC, Wadkar SB et al. Spectrophotometric and HPLC methods for simultaneous estimation of amlodipine besilate, losartan potassium and hydrochlorothiazide in tablets. Indian J Pharm Sci 2010; 72: 136–140
- [28] Tabrizi AB. A new spectrofluorimetric method for determination of nifedipine in pharmaceutical formulations. Chem Analityczna 2007; 52: 635–643
- [29] Özaltin N, Yardimci C.IS Determination of nifedipine in human plasma by square wave adsorptive stripping voltammetry. J Pharm Biomed Anal 2002; 30: 573–582
- [30] Chatki PK, Hotha KK, Kolagatla PRR et al. LC-MS/MS determination and pharmacokinetic study of lacidipine in human plasma. Biomed Chromatogr 2013; 27: 838–845
- [31] Tiwari RN, Shah N, Bhalani V et al. LC, MSn and LC-MS/MS studies for the characterization of degradation products of amlodipine. J Pharm Anal 2015; 5: 33–42 Im Internet http://dx.doi.org/10.1016/j. jpha.2014.07.005